PDGFRL Inhibitors
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Originally developed as a BCR-ABL tyrosine kinase inhibitor for chronic myeloid leukemia (CML), imatinib also inhibits PDGFR and other tyrosine kinases. It has been used for gastrointestinal stromal tumors (GISTs) and other cancers. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Another tyrosine kinase inhibitor studied in the research of CML and Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL). It also targets PDGFR and other kinases. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
This multi-targeted receptor tyrosine kinase inhibitor has been used for renal cell carcinoma (RCC), GISTs, and pancreatic neuroendocrine tumors. It targets PDGFR, VEGFR, c-KIT, and other receptors. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Used for advanced renal cell carcinoma, hepatocellular carcinoma, and thyroid cancer, sorafenib is a multi-kinase inhibitor that targets PDGFR, VEGFR, RAF kinases, and more. | ||||||
BIBF1120 | 656247-17-5 | sc-364433 sc-364433A | 5 mg 10 mg | $184.00 $321.00 | 2 | |
Approved for idiopathic pulmonary fibrosis and systemic sclerosis-associated interstitial lung disease, nintedanib inhibits multiple tyrosine kinases including PDGFR, VEGFR, and FGFR. | ||||||
AP 24534 | 943319-70-8 | sc-362710 sc-362710A | 10 mg 50 mg | $175.00 $983.00 | 2 | |
Originally developed for resistant CML and ALL, ponatinib also inhibits PDGFR and other kinases. | ||||||